Patent classifications
A61P3/02
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
The invention relates to compounds of formula I: ##STR00001##
where a, R.sup.1, and R.sup.3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
The present disclosure relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular, in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.
Topical regional neuro-affective therapy with cannabinoids
A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) to the back of the neck of a human patient to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the cannabinoid drug(s) are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.
Oral/enteral vegetarian food compositions and method of manufacturing the same
Vegetarian oral and enteral foods and processes for manufacturing the same from either fresh ingredients or powder ingredients are disclosed comprising: a high-protein vegetable group having a first predetermined percentage (%) weight; a carbohydrate group having a second predetermined percentage (%) weight; a fiber group having a fourth predetermined percentage (%) weight; purified water having a sixth predetermined percentage (%) weight, enzyme having a fourth percentage (%) weight; and a supplement of vitamins and minerals having a fifth percentage (%) weight, all undergon an enzymatic hydrolysis to achieve a calorie density of 1 kcal/ml; a viscosity less than 100 cP; a peptide less than 10 kDa; a plurality of amino acids and vitamins.
ENCAPSULATED FOOD PRODUCTS AND METHODS OF MAKING SAME
The present disclosure relates to a method of preparing non-gelatin soft capsules filled with an edible semi-solid or liquid material, the method comprising the general step of thermoforming a gentled film (membrane) into capsule that will be filled with (primarily) food and/or beverages.
MIXTURE OF NON-DIGESTIBLE OLIGOSACCHARIDES FOR STIMULATING THE IMMUNE SYSTEM
Nutritional compositions with fucosyllactose and betagalactooligosaccharides for use in stimulation of the immune system. The composition is suitable for infants.
STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE
The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace 02 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
Method of extracting nutrients from a plant
A method of extracting nutrients from a plant includes the steps of: pulverizing a water soluble nutrient-based plant part of a first plant material of the plant so as to form a first pulverized plant part; pulverizing a lipid soluble nutrient-based plant part of a second plant material of the plant so as to form a second pulverized plant part; subjecting the first pulverized plant part to a distillation so as to obtain a distillate and a first residue that contains a water soluble nutrient; and immersing the second pulverized plant part in the distillate to form a first mixture followed by distillation of the first mixture, so as to obtain a second residue that contains a lipid soluble nutrient.
Carbamoyl phenylalaninol compounds and uses thereof
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.
COMPOUNDS, COMPOSITIONS, METHODS, AND KITS RELATING TO TELOMERE EXTENSION
Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.